We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma's $370B Bet on America: The ETF Plays for 2026
Read MoreHide Full Article
Key Takeaways
U.S. pharma entered a rebound in 2025, with a $370B domestic investment pledge reshaping the industry.
Tariff threats and MFN pricing deals pushed firms like Eli Lilly to expand U.S. manufacturing capacity.
ETFs such as IHE offer diversified exposure to pharma's growth while reducing single-stock risks.
The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a complex mix of regulatory incentives and tariff threats, which resulted in a new investment landscape for drugmakers.
Evidently, the Dow Jones U.S. Pharmaceuticals Index has returned roughly 23% year to date, outpacing its single-digit return in 2024 and also the broader market’s return, with the Dow Jones Industrial Average up 13.1% so far this year. Such a stark rebound reflects investors’ regained confidence in high-quality drugmakers with visible earnings and rich pipelines.
As we enter 2026, the industry is moving into an investment ‘super-cycle,’ with major drugmakers pledging a staggering $370 billion toward U.S. projects over the next five years, as per the new fourth-quarter market trend report from California-based contractor and construction manager DPR Construction.
This capital influx comes from renowned pharmaceutical heavyweights, such as Eli Lilly (LLY - Free Report) , Johnson & Johnson (JNJ - Free Report) , Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) , who have committed billions of dollars’ worth of investments in the United States this year. Designed to reinforce the domestic drug supply chain, these initiatives should also enhance profitability for the companies involved and for pharmaceutical ETFs with exposure to them.
Before highlighting a few pharma ETFs that could be added to your watchlist for exposure to the U.S. pharmaceutical industry’s expected growth, let us first examine the catalysts behind this massive investment commitment and, in turn, the industry’s growth prospects. The idea is to help you make an informed decision.
Catalysts Supporting the Investment Surge
The monumental wave of corporate investment that the U.S. pharma industry witnessed this year is a direct response to a series of policy actions. The primary driver is the Trump administration's aggressive stance on trade and drug pricing, which has created both a "stick" and a "carrot" for the industry.
The ‘stick’ has been the credible threat of steep tariffs on pharmaceuticals imported into the United States. This risk can be underscored by a Truth Social post on Sept. 25, 2025, in which Trump warned of a 100% tariff on branded drugs beginning Oct. 1, 2025, unless companies invested in U.S.-based manufacturing.
These tariff threats pushed both domestic and foreign drugmakers to invest in U.S. pharmaceutical manufacturing to avoid potential penalties. For instance, British pharmaceutical firm GSK Plc (GSK - Free Report) pledged in mid-September to invest $30 billion in research and manufacturing in the United States over the next five years, while domestic drugmaker MRK announced its investment plan in the United States worth $70 billion through 2030, in October, aimed at expanding domestic manufacturing and R&D.
On the other hand, the U.S. administration offered a "carrot" through negotiated Most-Favored-Nation (“MFN”) pricing agreements. These deals, struck with companies like Eli Lilly and Novartis (NVS - Free Report) , offer reduced regulatory pressure and temporary tariff relief in exchange for lower U.S. drug prices and, critically, pledges for massive domestic investment. For example, Eli Lilly committed to at least $27 billion in new U.S. manufacturing, while Novo Nordisk pledged an additional $10 billion to strengthen its domestic footprint as part of its agreement.
Supporting this shift, the FDA launched the PreCheck program to streamline and accelerate the regulatory review process for new domestic manufacturing facilities, aiming to remove a key bureaucratic hurdle to onshoring. This should ensure the supply chain for critical medicines remains exclusively American.
The Investment Case for U.S. Pharma ETFs
The aforementioned discussion, reflecting a huge investment surge in the U.S. pharma industry, undoubtedly sets a bullish outlook for 2026. To this end, a report from the Precedence Research firm has predicted that the U.S. pharmaceutical market size will grow 6.2% year over year to $552.72 billion in 2026.
For investors, this landscape underscores a key challenge in picking individual winners in the pharma market. This is because the success of each massive capital project depends on execution, regulatory approval and future drug pipelines.
Amid this backdrop, gaining exposure to the market’s growth value through Pharma ETFs offers a prudent strategy. ETFs provide instant diversification across the industry, allowing investors to capture the overall growth from the $370 billion domestic investment while mitigating the volatility associated with any single company's clinical trials or construction delays.
This fund, with assets worth $838.5 million, offers exposure to 43 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines. Its top three holdings include LLY (26.00%), JNJ (22.53%) and MRK (4.45%).
IHE has surged 30.8% year to date. The fund charges 38 basis points (bps) as fees. It traded at a volume of 0.07 million shares in the last trading session.
This fund, with a market value worth $318.2 million, offers exposure to 30 US pharmaceutical companies. Its top five holdings include JNJ (5.12%), Abbott Laboratories (ABT - Free Report) (5.00%), MRK (5.00%), PFE (4.98%) and ABBV (4.90%).
PJP has soared 29.2% year to date. The fund charges 57 bps as fees. It traded at a volume of 0.01 million shares in the last trading session.
This fund, with total net assets worth $1.19 billion, offers exposure to 26 most liquid pharmaceutical companies. Its top five holdings include LLY (24.26%), NVS (9.14%), MRK (7.84%), NVS (5.94%) and GSK (4.75%).
PPH has soared 19.6% year to date. The fund charges 35 bps as fees. It traded at a volume of 0.54 million shares in the last trading session.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pharma's $370B Bet on America: The ETF Plays for 2026
Key Takeaways
The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a complex mix of regulatory incentives and tariff threats, which resulted in a new investment landscape for drugmakers.
Evidently, the Dow Jones U.S. Pharmaceuticals Index has returned roughly 23% year to date, outpacing its single-digit return in 2024 and also the broader market’s return, with the Dow Jones Industrial Average up 13.1% so far this year. Such a stark rebound reflects investors’ regained confidence in high-quality drugmakers with visible earnings and rich pipelines.
As we enter 2026, the industry is moving into an investment ‘super-cycle,’ with major drugmakers pledging a staggering $370 billion toward U.S. projects over the next five years, as per the new fourth-quarter market trend report from California-based contractor and construction manager DPR Construction.
This capital influx comes from renowned pharmaceutical heavyweights, such as Eli Lilly (LLY - Free Report) , Johnson & Johnson (JNJ - Free Report) , Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) , who have committed billions of dollars’ worth of investments in the United States this year. Designed to reinforce the domestic drug supply chain, these initiatives should also enhance profitability for the companies involved and for pharmaceutical ETFs with exposure to them.
Before highlighting a few pharma ETFs that could be added to your watchlist for exposure to the U.S. pharmaceutical industry’s expected growth, let us first examine the catalysts behind this massive investment commitment and, in turn, the industry’s growth prospects. The idea is to help you make an informed decision.
Catalysts Supporting the Investment Surge
The monumental wave of corporate investment that the U.S. pharma industry witnessed this year is a direct response to a series of policy actions. The primary driver is the Trump administration's aggressive stance on trade and drug pricing, which has created both a "stick" and a "carrot" for the industry.
The ‘stick’ has been the credible threat of steep tariffs on pharmaceuticals imported into the United States. This risk can be underscored by a Truth Social post on Sept. 25, 2025, in which Trump warned of a 100% tariff on branded drugs beginning Oct. 1, 2025, unless companies invested in U.S.-based manufacturing.
These tariff threats pushed both domestic and foreign drugmakers to invest in U.S. pharmaceutical manufacturing to avoid potential penalties. For instance, British pharmaceutical firm GSK Plc (GSK - Free Report) pledged in mid-September to invest $30 billion in research and manufacturing in the United States over the next five years, while domestic drugmaker MRK announced its investment plan in the United States worth $70 billion through 2030, in October, aimed at expanding domestic manufacturing and R&D.
On the other hand, the U.S. administration offered a "carrot" through negotiated Most-Favored-Nation (“MFN”) pricing agreements. These deals, struck with companies like Eli Lilly and Novartis (NVS - Free Report) , offer reduced regulatory pressure and temporary tariff relief in exchange for lower U.S. drug prices and, critically, pledges for massive domestic investment. For example, Eli Lilly committed to at least $27 billion in new U.S. manufacturing, while Novo Nordisk pledged an additional $10 billion to strengthen its domestic footprint as part of its agreement.
Supporting this shift, the FDA launched the PreCheck program to streamline and accelerate the regulatory review process for new domestic manufacturing facilities, aiming to remove a key bureaucratic hurdle to onshoring. This should ensure the supply chain for critical medicines remains exclusively American.
The Investment Case for U.S. Pharma ETFs
The aforementioned discussion, reflecting a huge investment surge in the U.S. pharma industry, undoubtedly sets a bullish outlook for 2026. To this end, a report from the Precedence Research firm has predicted that the U.S. pharmaceutical market size will grow 6.2% year over year to $552.72 billion in 2026.
For investors, this landscape underscores a key challenge in picking individual winners in the pharma market. This is because the success of each massive capital project depends on execution, regulatory approval and future drug pipelines.
Amid this backdrop, gaining exposure to the market’s growth value through Pharma ETFs offers a prudent strategy. ETFs provide instant diversification across the industry, allowing investors to capture the overall growth from the $370 billion domestic investment while mitigating the volatility associated with any single company's clinical trials or construction delays.
Pharma ETFs to Consider
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This fund, with assets worth $838.5 million, offers exposure to 43 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines. Its top three holdings include LLY (26.00%), JNJ (22.53%) and MRK (4.45%).
IHE has surged 30.8% year to date. The fund charges 38 basis points (bps) as fees. It traded at a volume of 0.07 million shares in the last trading session.
Invesco Pharmaceuticals ETF (PJP - Free Report)
This fund, with a market value worth $318.2 million, offers exposure to 30 US pharmaceutical companies. Its top five holdings include JNJ (5.12%), Abbott Laboratories (ABT - Free Report) (5.00%), MRK (5.00%), PFE (4.98%) and ABBV (4.90%).
PJP has soared 29.2% year to date. The fund charges 57 bps as fees. It traded at a volume of 0.01 million shares in the last trading session.
VanEck Pharmaceutical ETF (PPH - Free Report)
This fund, with total net assets worth $1.19 billion, offers exposure to 26 most liquid pharmaceutical companies. Its top five holdings include LLY (24.26%), NVS (9.14%), MRK (7.84%), NVS (5.94%) and GSK (4.75%).
PPH has soared 19.6% year to date. The fund charges 35 bps as fees. It traded at a volume of 0.54 million shares in the last trading session.